February 2023 ACIP Meeting - RSV Vaccines - Pediatric/Maternal

Cost effectiveness analysis for nirsevimab - CDC model; Cost effectiveness analysis for nirsevimab - Comparison to manufacturer
model; Evidence to Recommendations framework for nirsevimab; Clinical considerations for nirsevimab; Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine; Workgroup considerations
This video can also be viewed at
www.cdc.gov/vaccines/videos/low-res/ACIPFeb2023/ACIP-6_RSV_Vaccines-Pediatric-Maternal_02-23-2023_LowRes.mp4